UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma

Journal of clinical oncology, 2012-05, Vol.30 (14), p.1678-1685

2012

Link zum Volltext

Verfügbarkeit prüfen

Serum Prostate-Specific Antigen Decline as a Marker of Clinical Outcome in Hormone-Refractory Prostate Cancer Patients: Association With Progression-Free Survival, Pain End Points, and Survival

Journal of clinical oncology, 2001-03, Vol.19 (5), p.1304-1311

2001

Link zum Volltext

Verfügbarkeit prüfen

Anticancer therapy targeting the erbB family of receptor tyrosine kinases

Seminars in oncology, 2001-10, Vol.28 (5N), p.67-79, Article asonc02805n0067

2001

Link zum Volltext

Verfügbarkeit prüfen

The Current Status of Camptothecin Analogues as Antitumor Agents

JNCI : Journal of the National Cancer Institute, 1993-02, Vol.85 (4), p.271-291

1993

Link zum Volltext

Verfügbarkeit prüfen

Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone

Journal of clinical oncology, 2000-04, Vol.18 (7), p.1440-1450

2000

Link zum Volltext

Verfügbarkeit prüfen

Reanalysis of cancer drugs: Old drugs, new tricks

Clinical cancer research, 2004-06, Vol.10 (11), p.3897-3907

2004

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4088: First-in-human dose selection for ALKS 4230, an investigational immunotherapeutic agent

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.4088-4088

2017

Link zum Volltext

Verfügbarkeit prüfen

Reply to M. Sun et al

Journal of clinical oncology, 2012-11, Vol.30 (31), p.3902-3902

2012

Link zum Volltext

Verfügbarkeit prüfen

Intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in a phase I study of patients with advanced solid tumors

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS2649-TPS2649

2019

Link zum Volltext

Verfügbarkeit prüfen

CI-1033, a pan-erbB tyrosine kinase inhibitor

Seminars in oncology, 2001-10, Vol.28 (5N), p.80-85, Article asonc02805n0080

2001

Link zum Volltext

Verfügbarkeit prüfen

Phase Ib trial of the CpG-A Oligonucleotide CMP-001 combined with pembrolizumab (Pembro) in patients with advanced melanoma

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS9593-TPS9593

2016

Link zum Volltext

Verfügbarkeit prüfen

Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage

Cancer research (Chicago, Ill.), 1993-09, Vol.53 (18), p.4164-4168

1993

Link zum Volltext

Verfügbarkeit prüfen

Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.4501-4501

2012

Link zum Volltext

Verfügbarkeit prüfen

Anticancer therapy targeting the erbB family of receptor tyrosine kinases

Seminars in oncology, 2001-10, Vol.28 (5), p.67-79

2001

Link zum Volltext

Verfügbarkeit prüfen

Taxol: a new and effective anti-cancer drug

Anti-cancer drugs, 1991-12, Vol.2 (6), p.519-530

1991

Link zum Volltext

Verfügbarkeit prüfen

CI-1033, a pan-erbB tyrosine kinase inhibitor

Seminars in oncology, 2001-10, Vol.28 (5), p.80-85

2001

Link zum Volltext

Verfügbarkeit prüfen

New Natural Products in Cancer Chemotherapy

Journal of clinical pharmacology, 1990-09, Vol.30 (9), p.770-788

1990

Link zum Volltext

Verfügbarkeit prüfen

Reanalysis of Cancer Drugs

Clinical cancer research, 2004-06, Vol.10 (11), p.3897-3907

2004

Link zum Volltext

Verfügbarkeit prüfen

Camptothecin analogues : studies from the Johns Hopkins oncology center

Cancer chemotherapy and pharmacology, 1994-01, Vol.34 (S1), p.S53-S57

1994

Link zum Volltext

Verfügbarkeit prüfen

Recent clinical advances with camptothecin analogues

Cancer treatment and research, 1995, Vol.78, p.29

1995

Link zum Volltext

Verfügbarkeit prüfen

Response of metastatic adenoid cystic carcinoma and Merkel cell tumor to high-dose Melphalan with autologous bone marrow transplantation

Investigational new drugs, 1992-04, Vol.10 (1), p.45-48

1992

Link zum Volltext

Verfügbarkeit prüfen

Chronic vasculitis causing unilateral ureteral stenosis

Urology (Ridgewood, N.J.), 1988-10, Vol.32 (4), p.354-356

1988

Link zum Volltext

Verfügbarkeit prüfen

The effect of cauterization of the rabbit ovary on adhesion formation

Fertility and sterility, 1986-10, Vol.46 (4), p.696-700

1986

Link zum Volltext

Verfügbarkeit prüfen

A Versatile Microcomputer Program for Data Management and Analysis in a Clinical Microbiology Laboratory

Proceedings - Symposium on Computer Application in Medical Care, 1985, p.460-464

1985

Link zum Volltext

Verfügbarkeit prüfen

A phase I trial of ALKS 4230, an engineered cytokine activator of NK and effector T cells, in patients with advanced solid tumors

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS3111-TPS3111

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(26)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(16)
Biological And Medical Sciences
(13)
Life Sciences & Biomedicine
(13)
Medical Sciences
(13)
Science & Technology
(13)
Antineoplastic Agents
(11)
Oncology
(11)
Pharmacology. Drug Treatments
(11)
Adult
(7)
Animals
(6)
Male
(6)
Aged
(5)
Antineoplastic Agents - Therapeutic Use
(5)
Camptothecin - Analogs & Derivatives
(5)
Camptothecin - Therapeutic Use
(5)
Chemotherapy
(5)
Female
(5)
Middle Aged
(5)
Topotecan
(5)
Irinotecan
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma

Serum Prostate-Specific Antigen Decline as a Marker of Clinical Outcome in Hormone-Refractory Prostate Cancer Patients: Association With Progression-Free Survival, Pain End Points, and Survival

Anticancer therapy targeting the erbB family of receptor tyrosine kinases

The Current Status of Camptothecin Analogues as Antitumor Agents

Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone

Reanalysis of cancer drugs: Old drugs, new tricks

Abstract 4088: First-in-human dose selection for ALKS 4230, an investigational immunotherapeutic agent

Reply to M. Sun et al

Intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in a phase I study of patients with advanced solid tumors

CI-1033, a pan-erbB tyrosine kinase inhibitor

Phase Ib trial of the CpG-A Oligonucleotide CMP-001 combined with pembrolizumab (Pembro) in patients with advanced melanoma

Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage

Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial

Anticancer therapy targeting the erbB family of receptor tyrosine kinases

Taxol: a new and effective anti-cancer drug

CI-1033, a pan-erbB tyrosine kinase inhibitor

New Natural Products in Cancer Chemotherapy

Reanalysis of Cancer Drugs

Camptothecin analogues : studies from the Johns Hopkins oncology center

Recent clinical advances with camptothecin analogues

Response of metastatic adenoid cystic carcinoma and Merkel cell tumor to high-dose Melphalan with autologous bone marrow transplantation

Chronic vasculitis causing unilateral ureteral stenosis

The effect of cauterization of the rabbit ovary on adhesion formation

A Versatile Microcomputer Program for Data Management and Analysis in a Clinical Microbiology Laboratory

A phase I trial of ALKS 4230, an engineered cytokine activator of NK and effector T cells, in patients with advanced solid tumors

Suchergebnisse filtern